Future Querying: Can LLMs Serve as Implicit Medical World Models?

Deploying clinical ML is slow and brittle: models that work at one hospital often degrade under distribution shifts at the next. In this work, we study a simple question -- can large language models (LLMs) create portable patient embeddings i.e. representations of patients enable a downstream predictor built on one hospital to be used elsewhere with minimal-to-no retraining and fine-tuning. To do so, we map from irregular ICU time series onto concise natural language summaries using a frozen LLM, then embed each summary with a frozen text embedding model to obtain a fixed length vector capable of serving as input to a variety of downstream predictors. Across three cohorts (MIMIC-IV, HIRID, PPICU), on multiple clinically grounded forecasting and classification tasks, we find that our approach is simple, easy to use and competitive with in-distribution with grid imputation, self-supervised representation learning, and time series foundation models, while exhibiting smaller relative performance drops when transferring to new hospitals. We study the variation in performance across prompt design, with structured prompts being crucial to reducing the variance of the predictive models without altering mean accuracy. We find that using these portable representations improves few-shot learning and does not increase demographic recoverability of age or sex relative to baselines, suggesting little additional privacy risk. Our work points to the potential that LLMs hold as tools to enable the scalable deployment of production grade predictive models by reducing the engineering overhead.

Recently, Large Language Models (LLMs) have gained significant traction in medical domain, especially in developing a QA systems to Medical QA systems for enhancing access to healthcare in low-resourced settings. This paper compares five LLMs deployed between April 2024 and August 2025 for medical QA, using the iCliniq dataset, containing 38,000 medical questions and answers of diverse specialties. Our models include Llama-3-8B-Instruct, Llama 3.2 3B, Llama 3.3 70B Instruct, Llama-4-Maverick-17B-128E-Instruct, and GPT-5-mini. We are using a zero-shot evaluation methodology and using BLEU and ROUGE metrics to evaluate performance without specialized fine-tuning. Our results show that larger models like Llama 3.3 70B Instruct outperform smaller models, consistent with observed scaling benefits in clinical tasks. It is notable that, Llama-4-Maverick-17B exhibited more competitive results, thus highlighting evasion efficiency trade-offs relevant for practical deployment. These findings align with advancements in LLM capabilities toward professional-level medical reasoning and reflect the increasing feasibility of LLM-supported QA systems in the real clinical environments. This benchmark aims to serve as a standardized setting for future study to minimize model size, computational resources and to maximize clinical utility in medical NLP applications.

Predicting future clinical outcomes from electronic health records (EHR) remains challenging due to the complexity and heterogeneity of patient data. LLMs have shown strong potential for such predictive tasks, yet existing approaches mainly focus on enhancing medical knowledge through distillation or RAG while relying on the model's internal ability to interpret contextual information. In this work, we present ReMedi (Reasoner for Medical Clinical Prediction), a framework for improving clinical outcome prediction from EHR. ReMedi generates rationale-answer pairs using a challenging sample regeneration mechanism for complex clinical questions, which leverages ground-truth answers as hints to enhance reasoning for further fine-tuning and preference tuning. ReMedi integrates ground-truth outcome guidance into the preference data construction loop, regenerating rationale-answer variants. By tuning on these rationale-answer pairs, the model improves its predictive performance. Experiments on multiple EHR prediction tasks demonstrate substantial gains of up to 19.9 percent over state-of-the-art baselines in terms of F1 score, underscoring ReMedi's effectiveness in real-world clinical prediction.